Sarepta Therapeutics, Inc. reported $1.97B of revenue over the trailing twelve months, −20% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.97B (to Q2 2026). Net income: −$137M, trailing twelve months to Q2 2026. Free cash flow: $82M, trailing twelve months to Q2 2026. Operating margin: −17%, trailing twelve months to Q2 2026.

SRPTSarepta Therapeutics, Inc.

Healthcare

$17.85+2.4% 1Y

$17.85

$15.0052 weeks$24.45

SRPT as reported

Sarepta Therapeutics, Inc. reported $1.97B of revenue over the trailing twelve months, −20% on the year before. 10 reported series are charted on this page, each one as filed.

$1.97B

Revenue, trailing twelve months · to Q2 2026 · −20% against the twelve months before

Net income: −$137M
Net income · +136% year on year · trailing twelve months to Q2 2026
Free cash flow: $82M
Free cash flow · −118% year on year · trailing twelve months to Q2 2026
Operating margin: −17%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SRPT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.97B	−20%	Q2 2026
Net income	−$137M	+136%	Q2 2026
EPS	−$1.60	+84%	Q2 2026
Gross margin	43%	n/a	Q4 2025
Operating margin	−17%	n/a	Q2 2026
Net margin	−15%	n/a	Q2 2026
ROE	−19%	n/a	Q2 2026
ROA	−6.9%	n/a	Q2 2026
ROIC	−20%	n/a	Q2 2026
Free cash flow	$82M	−118%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.